Clinical trial Recruiting at 1 site Observational Ages 65 and up

Evaluating the CALLY Index for Predicting Delirium After Hip Surgery in Older Patients

Official title: Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergoing Hip Fracture Surgery

Run by Ankara Ataturk Sanatorium Training and Research Hospital · NCT06818409 · Data updated 2026-11-12

This study is testing if a new index can help predict delirium in older patients after they have hip surgery.

More Hip Fracture trials

Quick facts

Study typeObservational
Ages65 Years and up
SexAll
Enrollment100 (estimated)
SponsorAnkara Ataturk Sanatorium Training and Research Hospital
Government
Locations1 site (Ankara, Keçiören)
StatusRecruiting
StartedFebruary 6, 2025
Main results expectedAugust 6, 2025
Study endsDecember 31, 2025
Registry record updatedFebruary 14, 2025
Trial IDNCT06818409 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients aged 65 years and older who are scheduled for surgery due to femoral neck or intertrochanteric fractures.

Probably not a fit

Patients with preoperative delirium, dementia, or other significant comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of the CRP-Albumin-Lymphocyte (CALLY) Index in predicting postoperative delirium (POD) in geriatric patients undergoing hip fracture surgery. It focuses on patients aged 65 and older, monitoring various biomarkers associated with delirium. The study will utilize the DSM-5 criteria for diagnosing delirium and will screen patients daily for signs of POD following their surgical procedures. The findings could help identify at-risk patients and improve postoperative care.

Why it matters

Potential benefit: If successful, this study could lead to better prediction and management of postoperative delirium, potentially reducing hospital stays and improving outcomes for elderly patients.

How similar studies have gone: While the approach of using biomarkers for predicting POD is gaining interest, the specific use of the CALLY Index in this context is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged 65 years and older who undergo surgery for femoral neck or intertrochanteric fractures

Exclusion Criteria:

* Patients with preoperative delirium
* Patients with preoperative dementia
* Patients with pathological fractures
* Patients with open fractures
* Patients with systemic or localized infections in the fracture region during the preoperative period
* Patients with multiple trauma
* Patients with a BMI \<18.5 or ≥35
* Patients with chronic organ failure
* Patients with advanced-stage cancer

Where it's running

  • University of Health Sciences, Ankara Atatürk Sanatorium Training and Research Hospital
    Ankara, Keçiören, Turkey (Türkiye)
    Recruiting

Study contacts

  • Principal investigator: Erbil Türksal, Specialist — University of Health Sciences, Ankara Atatürk Sanatorium Training and Research Hospital
  • Study coordinator: ERBİL TÜRKSAL, Specialist
  • Email: drerbilturksal@hotmail.com
  • Phone: 530 228 1319

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.